Herreros-Villanueva M, Zubia-Olascoaga A, Bujanda L. c-Met in pancreatic cancer stem cells: Therapeutic implications. World J Gastroenterol 2012; 18(38): 5321-5323 [PMID: 23082047 DOI: 10.3748/wjg.v18.i38.5321]
Corresponding Author of This Article
Luis Bujanda, MD, PhD, Department of Gastroenterology, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), Donostia Hospital-Biodonostia Institute, University of the Basque Country, 20014 San Sebastian, Spain. luis.bujanda@osakidetza.net
Article-Type of This Article
Field Of Vision
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Oct 14, 2012; 18(38): 5321-5323 Published online Oct 14, 2012. doi: 10.3748/wjg.v18.i38.5321
c-Met in pancreatic cancer stem cells: Therapeutic implications
Marta Herreros-Villanueva, Aizpea Zubia-Olascoaga, Luis Bujanda
Marta Herreros-Villanueva, Division of Oncology Research, Department of Medicine, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, United States
Aizpea Zubia-Olascoaga, IkerChem, Oncology Therapeutics Department, 20009 San Sebastian, Spain
Luis Bujanda, Department of Gastroenterology, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), Donostia Hospital-Biodonostia Institute, University of the Basque Country, 20014 San Sebastian, Spain
Author contributions: Herreros-Villanueva M, Zubia-Olascoaga A and Bujanda L designed and wrote the review.
Correspondence to: Luis Bujanda, MD, PhD, Department of Gastroenterology, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), Donostia Hospital-Biodonostia Institute, University of the Basque Country, 20014 San Sebastian, Spain. luis.bujanda@osakidetza.net
Telephone: +34-94-3007173 Fax: +34-94-3007065
Received: June 29, 2012 Revised: August 1, 2012 Accepted: August 3, 2012 Published online: October 14, 2012
Abstract
Pancreatic cancer is the deadliest solid cancer and currently the fourth most frequent cause of cancer-related deaths. Emerging evidence suggests that cancer stem cells (CSCs) play a crucial role in the development and progression of this disease. The identification of CSC markers could lead to the development of new therapeutic targets. In this study, the authors explore the functional role of c-Met in pancreatic CSCs, by analyzing self-renewal with sphere assays and tumorigenicity capacity in NOD SCID mice. They concluded that c-Met is a novel marker for identifying pancreatic CSCs and c-Methigh in a higher tumorigenic cancer cell population. Inhibition of c-Met with XL184 blocks self-renewal capacity in pancreatic CSCs. In pancreatic tumors established in NOD SCID mice, c-Met inhibition slowed tumor growth and reduced the population of CSCs, along with preventing the development of metastases.
